Geode Capital Management LLC Lowers Holdings in Elevance Health, Inc. $ELV

Geode Capital Management LLC lessened its stake in Elevance Health, Inc. (NYSE:ELV) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,124,599 shares of the company’s stock after selling 19,305 shares during the quarter. Geode Capital Management LLC’s holdings in Elevance Health were worth $1,797,009,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. Sound View Wealth Advisors Group LLC raised its position in shares of Elevance Health by 3.0% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock worth $354,000 after purchasing an additional 29 shares during the last quarter. Fulton Breakefield Broenniman LLC raised its position in Elevance Health by 3.6% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock worth $289,000 after buying an additional 29 shares during the last quarter. Perigon Wealth Management LLC raised its position in Elevance Health by 2.2% in the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock worth $481,000 after buying an additional 29 shares during the last quarter. Savvy Advisors Inc. raised its position in Elevance Health by 3.2% in the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock worth $343,000 after buying an additional 30 shares during the last quarter. Finally, CoreCap Advisors LLC raised its position in Elevance Health by 6.1% in the 4th quarter. CoreCap Advisors LLC now owns 557 shares of the company’s stock worth $195,000 after buying an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

ELV has been the subject of a number of research analyst reports. Citigroup upgraded shares of Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Guggenheim lifted their price target on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Royal Bank Of Canada lowered shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target for the company. in a research note on Tuesday, February 3rd. Bank of America upgraded shares of Elevance Health from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $405.00 to $435.00 in a research note on Wednesday, April 29th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $403.11.

Elevance Health Price Performance

NYSE ELV opened at $392.47 on Friday. The company has a 50-day moving average price of $341.76 and a 200-day moving average price of $338.51. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $408.00. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $85.23 billion, a P/E ratio of 16.69, a PEG ratio of 2.21 and a beta of 0.66.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm’s revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the firm posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities research analysts anticipate that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.